WallStreetZenWallStreetZen

NASDAQ: CARA
Cara Therapeutics Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for CARA

Based on 3 analysts offering 12 month price targets for Cara Therapeutics Inc.
Min Forecast
$20.00+77.94%
Avg Forecast
$26.33+134.28%
Max Forecast
$30.00+166.9%

Should I buy or sell CARA stock?

Based on 3 analysts offering ratings for Cara Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CARA stock forecasts and price targets.

CARA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Canaccord Genuity
Bottom 12%
12
Strong BuyMaintains$29.00+158.01%2022-03-14
HC Wainwright & Co.
Bottom 4%
4
BuyMaintains$30.00+166.90%2022-03-14
JP Morgan
Top 8%
93
Strong BuyUpgrades$20.00+77.94%2022-03-08Find out why

1 of 1

Forecast return on equity

Is CARA forecast to generate an efficient return?
Company
43.03%
Industry
14.81%
Market
62.61%
CARA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CARA forecast to generate an efficient return on assets?
Company
37.25%
Industry
13.32%
CARA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CARA earnings per share forecast

What is CARA's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$1.34
Avg 2 year Forecast
-$0.10
Avg 3 year Forecast
$1.00

CARA revenue forecast

What is CARA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$61.0M+54.59%
Avg 2 year Forecast
$165.9M+320.69%
Avg 3 year Forecast
$247.3M+527.3%
CARA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CARA revenue growth forecast

How is CARA forecast to perform vs Biotechnology companies and vs the US market?
Company
85.39%
Industry
23.98%
Market
6.66%
CARA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CARA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CARA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CARA$11.24$26.33+134.28%Strong Buy
ICPT$14.68$23.75+61.78%Buy
TRDA$19.07$18.00-5.61%Hold
AVTE$24.79$27.00+8.91%Strong Buy
AVXL$7.65$31.00+305.23%Buy

Cara Therapeutics Stock Forecast FAQ

Is Cara Therapeutics Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CARA) stock is to Strong Buy CARA stock.

Out of 3 analysts, 2 (66.67%) are recommending CARA as a Strong Buy, 1 (33.33%) are recommending CARA as a Buy, 0 (0%) are recommending CARA as a Hold, 0 (0%) are recommending CARA as a Sell, and 0 (0%) are recommending CARA as a Strong Sell.

If you're new to stock investing, here's how to buy Cara Therapeutics stock.

What is CARA's earnings growth forecast for 2022-2024?

(NASDAQ: CARA) Cara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Cara Therapeutics's earnings in 2022 is -$88,517,000.On average, 6 Wall Street analysts forecast CARA's earnings for 2022 to be -$72,003,033, with the lowest CARA earnings forecast at -$83,824,427, and the highest CARA earnings forecast at -$61,793,648. On average, 6 Wall Street analysts forecast CARA's earnings for 2023 to be -$5,373,361, with the lowest CARA earnings forecast at -$37,613,525, and the highest CARA earnings forecast at $24,717,459.

In 2024, CARA is forecast to generate $53,733,607 in earnings, with the lowest earnings forecast at $16,657,418 and the highest earnings forecast at $153,140,780.

What is CARA's revenue growth forecast for 2022-2024?

(NASDAQ: CARA) Cara Therapeutics's forecast annual revenue growth rate of 85.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.98%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 6.66%.

Cara Therapeutics's revenue in 2022 is $39,427,000.On average, 5 Wall Street analysts forecast CARA's revenue for 2022 to be $3,275,170,814, with the lowest CARA revenue forecast at $2,642,618,792, and the highest CARA revenue forecast at $4,234,208,232. On average, 5 Wall Street analysts forecast CARA's revenue for 2023 to be $8,912,578,459, with the lowest CARA revenue forecast at $7,533,451,701, and the highest CARA revenue forecast at $10,960,043,820.

In 2024, CARA is forecast to generate $13,289,610,618 in revenue, with the lowest revenue forecast at $10,816,575,089 and the highest revenue forecast at $17,314,042,848.

What is CARA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: CARA) forecast ROA is 37.25%, which is higher than the forecast US Biotechnology industry average of 13.32%.

What is CARA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CARA price target, the average CARA price target is $26.33, with the highest CARA stock price forecast at $30.00 and the lowest CARA stock price forecast at $20.00.

On average, Wall Street analysts predict that Cara Therapeutics's share price could reach $26.33 by Mar 14, 2023. The average Cara Therapeutics stock price prediction forecasts a potential upside of 134.28% from the current CARA share price of $11.24.

What is CARA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: CARA) Cara Therapeutics's current Earnings Per Share (EPS) is -$1.67. On average, analysts forecast that CARA's EPS will be -$1.34 for 2022, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$1.15. On average, analysts forecast that CARA's EPS will be -$0.10 for 2023, with the lowest EPS forecast at -$0.70, and the highest EPS forecast at $0.46. In 2024, CARA's EPS is forecast to hit $1.00 (min: $0.31, max: $2.85).

What is CARA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: CARA) forecast ROE is 43.03%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.